Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $53.00 Price Target at Wells Fargo & Company

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target boosted by Wells Fargo & Company from $50.00 to $53.00 in a research note published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective for the company. The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.29.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $42.76 on Wednesday. The firm has a market cap of $3.24 billion, a PE ratio of 57.78 and a beta of 0.06. The business’s 50 day simple moving average is $42.90 and its 200 day simple moving average is $39.66. Kiniksa Pharmaceuticals International has a 52-week low of $18.25 and a 52-week high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.90% and a net margin of 8.71%.The firm had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. During the same period last year, the company earned ($0.12) EPS. The company’s revenue was up 65.0% compared to the same quarter last year. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,048 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the sale, the chief operating officer owned 16,666 shares in the company, valued at $692,638.96. This represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Barry D. Quart sold 20,129 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. The trade was a 61.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,623 shares of company stock valued at $5,236,389 over the last 90 days. 53.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC raised its position in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after purchasing an additional 250 shares during the period. Mariner LLC grew its stake in Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after buying an additional 266 shares during the last quarter. Virtus Investment Advisers LLC raised its holdings in Kiniksa Pharmaceuticals International by 2.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after acquiring an additional 406 shares during the period. Mercer Global Advisors Inc. ADV lifted its position in Kiniksa Pharmaceuticals International by 7.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Analysts at Wells Fargo raised their price target to $53 and kept an Overweight rating, implying roughly ~24% upside from the current share price. Benzinga
• Positive Sentiment: Wedbush also raised its price target to $53 and retained an Outperform rating, matching the Wells Fargo upside view and adding buy-side momentum. Benzinga
• Positive Sentiment: Kiniksa gave 2026 ARCALYST (rilonacept) net product revenue guidance of $900M–$920M; Q4 product revenue was $202.1M and full‑year 2025 net product revenue was $677.6M (y/y growth). The guidance and strong revenue growth support the commercial story. Q4 & Guidance Release
• Positive Sentiment: Balance sheet strengthened — cash increased by ~$170.4M in 2025 to $414.1M, giving the company runway to invest in commercialization and pipeline programs. Q4 & Guidance Release
• Positive Sentiment: Pipeline milestones: KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 — a positive potential catalyst if results are favorable. Q4 & Guidance Release
• Neutral Sentiment: Management will present at the TD Cowen Health Care Conference (March 2); investor presentation could provide color but is not a direct earnings catalyst. Conference Announcement
• Neutral Sentiment: Kiniksa plans to initiate KPL-1161 Phase 1 by year-end 2026 — longer-term pipeline news, not an immediate market mover. Q4 & Guidance Release
• Neutral Sentiment: Elevated options activity has drawn media attention, suggesting increased short-term trading interest but not confirming directional conviction. MSN Options Article
• Negative Sentiment: Q4 EPS missed expectations: reported $0.17 vs. consensus $0.29 — the earnings shortfall is the primary near-term negative catalyst pressuring the stock. Zacks Earnings Coverage

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.